Psychiatric Services
June 25, 2025
Michael Liu, Rachel Branning, Austin Lee et al.
2 citations
This study sought to investigate racial-ethnic disparities in the utilization of intravenous ketamine and intranasal esketamine therapy for major depressive disorder. The TriNetX platform was used to identify 861,179 patients diagnosed as having moderate-to-severe recurrent major depressive disorder between January 2019 and October 2024. Patients were divided into non-Hispanic White,...
Journal of Psychoactive Drugs
March 1, 2025
Alexsandra Kovacevich, Ian Dorney, Lukas Bobak et al.
1 citation
Olfactory dysfunction (OD) has become increasingly prevalent since the COVID-19 pandemic, yet effective treatments remain limited. In recent years, anecdotal reports have emerged on the potential benefits of serotonergic psychedelics (lysergic acid diethylamide [LSD], psilocybin, etc.) in improving OD. To date, only one case series in the medical literature has documented this phenomenon. This...
Translational Psychiatry
August 9, 2024
Yiheng Pan, Maria P Gorenflo, Pamela B. Davis et al.
14 citations
Ketamine has gained attention for its effective treatment for patients with major depressive disorder (MDD) and suicidal ideation; Despite numerous studies presenting the rapid efficacy, long-term benefit in real-world populations remains poorly characterized. This is a retrospective cohort study using TriNetX US Collaborative Network, a platform aggregating electronic health records (EHRs)...
Research Square
August 7, 2023
Rong Xu, Yiheng Pan, Maria P Gorenflo et al.
preprint
Abstract Ketamine, including esketamine, is an effective treatment for patients with treatment-resistant depression (TRD); however, its long-term efficacy in real-world populations remains poorly characterized. This is a retrospective cohort study using TriNetX US Collaborative Network, a platform aggregating electronic health records (EHRs) data from 93 million patients from 56 health care...
Addiction
February 15, 2023
Zhen-Xiang Gao, T. Winhusen, Maria P Gorenflo et al.
Background and aims: Cocaine use disorder (CUD) is a significant public health issue for which there is no Food and Drug Administration (FDA) approved medication. Drug repurposing looks for new cost-effective uses of approved drugs. This study presents an integrated strategy to identify repurposed FDA-approved drugs for CUD treatment. Design: Our drug repurposing strategy combines artificial...